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Background: The choice between heterologous expression versus chemical synthesis for synthesizing short
cysteine-rich insecticidal peptides from arthropods may impact the obtainment of yields and well-folded bioactive
molecules for scientific research. Therefore, two recombinant expression systems were compared to that of chemical
synthesis for producing Ba1, a cysteine-rich spider neurotoxin.
Methods: The transcription of the insecticidal neurotoxin Ba1 was obtained from a cDNA library of venom glands of
the spider Brachypelma albiceps. It was cloned into the pCR®2.1-TOPO® cloning vector and then introduced in two
different expression vectors, pQE40 and pET28a+. Each vector was transfected into E. coli M15 and BL21 cells,
respectively, and expressed under induction with isopropyl thiogalactoside (IPTG). The chemical synthesis of Ba1
was performed in an Applied Biosystems 433A peptide synthesizer.
Results: Both expression systems pQE40 and pET28a+ expressed the His-tagged recombinant protein products,
HisrDFHRBa1 and HisrBa1, respectively, as inclusion bodies. The recombinant proteins HisrDFHRBa1 and HisrBa1
presented respective molecular masses of 28,289 and 8274.6 Da, and were not biologically active. These results
suggested that both HisrDFHRBa1 and HisrBa1 were oxidized after cell extraction, and that their insecticidal activities
were affected by their N-terminal pro-peptides and different disulfide bridge arrangements. The respective protein
expression yields for HisrDFHRBa1 and HisrBa1 were 100 μg/L and 900 μg/L of culture medium. HisrBa1 was reduced
and folded under in vitro conditions. The in vitro folding of HisrBa1 produced several isoforms, one of which, after
removing its N-terminal pro-peptide by enzymatic cleavage, presented elevated insecticidal activities compared to the
native Ba1. Furthermore, the His-tagged protein HisrDFHRBa1 underwent enzymatic cleavage to obtain recombinant
Ba1 (rBa1). As expected, the molecular mass of rBa1 was 4406.4 Da. On the other hand, Ba1 was chemically synthesized
(sBa1) with a yield of 11 mg per 0.1 mmol of amino acid assembly.
Conclusions: The two recombinant insecticidal peptides and the one synthesized chemically were as active as the
native Ba1; however, toxin yields differed drastically.
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Insecticidal spider peptides contain unique properties
such as small size, resistance to proteolysis and strong af-
finities for cell receptors; therefore, they are essential tools
for finding and studying new insecticidal receptors with
the aim of designing novel and specific biopesticides or
conducting structure-function studies [1, 2]. Ba1 is an in-
secticidal toxin obtained from the venom of the therapho-
sid spider Brachypelma albiceps. The primary structure of
Ba1 comprises 39 residues and 6 half-cystines that form
three disulfide bridges. The three dimensional structure of
Ba1 was solved by NMR, and it contains three antiparallel
β-sheets and belongs to the DDH family of spider neuro-
toxins [3]. Although the cell receptor of Ba1 has not been
found, it is thought that its target is the voltage-gated
sodium channel (Nav) of insects because of its rapid and
strong insecticidal activity, which resembles that of the
known Nav neurotoxins from the venom of spiders and
scorpions [4, 5].
Since appreciable amounts of Ba1 are needed to con-
tinue the search for insect cell receptors and structure-
function studies, and because its natural extraction is quite
laborious and limited, the recombinant expression or
chemical synthesis of Ba1 could provide an alternative for
obtaining larger quantities of this insecticidal molecule for
further biochemical studies. Herein, we report the produc-
tion of a recombinant Ba1 using two expression systems as
well as the production of Ba1 by chemical synthesis. The
two expression systems selected used the plasmids pQE40
and pET28, which contain N-terminal pro-peptides of 190
and 22 residues, respectively. The two plasmids were se-
lected according to the manufacturer’s recommendations
and to scientific references for short peptide recombinant
expression [6–9]. Thus, we report the advantages and dis-
advantages of two expression systems as well as that of the
chemical synthesis for obtaining active cysteine-rich spider
peptides. This work may be of interest for researchers in
the field that face the decision to synthesize, biologically or
chemically, cysteine-rich peptide ligands from arthropods.
Methods
Bacterial strains, enzymes and plasmids
E. coli XL1 Blue was used for plasmid propagation. M15
and BL21 were used for the expression of the proteins.
Plasmids pCR®2.1-TOPO® (Invitrogen), pQE40 (Qiagen)
and pET28a+ (Novagen) were used for cloning and pro-
duction of the proteins linked to a 6His-tag. Restriction
enzymes, Taq polymerase, factor Xa and T4 DNA ligase
were purchased from New England Biolabs.
Gene cloning
Based on the information obtained from direct peptide
sequencing of Ba1, a specific oligonucleotide was designed
and used for the PCR reaction employing as a templatethe cDNA material obtained previously from a venom
gland cDNA library. The PCR reaction was performed in
Taq DNA polymerase buffer, 200 μM dNTPs, 0.25 μM
forward primer (5‘-ATTCTCGAATGTGTTTTCTCATG-
3’) 0.25 μM; reverse CDS3’primer (5‘-AATCTTCAGACA
CAACTTGATC-3’) and two units of Taq DNA polymer-
ase in a final volume of 50 μL in a Perkin Elmer 9600 in-
strument. The reaction was incubated at 94 °C for three
minutes and, after the initial cycle, the mixture was incu-
bated at 94 °C for 30 s, 60 °C for one minute and 72 °C for
one minute for 30 cycles, followed by a final seven-minute
step at 72 °C. PCR products were purified using the High
Pure Plasmid Isolation Kit (Roche) following the manufac-
turer’s instructions, and then ligated into a pCR®2.1-
TOPO® + EcoR1-digested plasmid. The ligation reaction
was used to transform competent E. coli XL1 Blue cells.
Positive clones were sequenced from both ends using the
Thermo sequence radiolabeled terminator cycle sequen-
cing kit (Amersham).
Plasmid construction
The DNA fragment encoding the Ba1 sequence, preceded
by factor Xa recognition site was amplified by PCR from a
cDNA clone obtained from the library previously described.
Appropriate oligonucleotides were designed for introdu-
cing the enzymatic restriction sites BglII and PstI for direc-
tional insertion into pQE40. The PCR-amplified product
was cloned into pCR®2.1-TOPO®, digested with EcoRI and
subcloned using standard methods. The PCR amplifica-
tions were carried out using the following oligonucleotides:
Ba1Bgl corresponds to 5’-CGCAGATCTATCGAGGGAA
GGATTCTCGAATGTGTTTTCTCATG-3’, and Ba1P: 5’-
CGCCTGCAGTTACTAAATCTTCAGACACAACTTGA
TC-3’. The PCR conditions were: three minutes at 94 °C,
30 cycles for 30 s at 94 °C, one minute at 60 °C, one
minute at 72 °C, and a final extension of seven minutes at
72 °C. The PCR products and the corresponding plasmids
were digested with the corresponding restriction enzymes
at 37 °C overnight. PCR products were purified using the
High Pure Plasmid Isolation Kit (Roche) before ligation.
The ligation reaction (20 μL) was carried out with T4
DNA ligase with a 10-fold insert excess over plasmid for
16 h at 16 °C; ten microliters of the ligation reaction were
used to transfect competent E. coli XL1 Blue cells. Positive
clones with the expected insert were grown in LB ampi-
cillin medium. The plasmids of positive colonies were puri-
fied by means of the High Pure Plasmid Isolation Kit
(Roche). Plasmid constructs were verified by sequencing
from both sites, the insert boundaries to confirm the read-
ing frame and conservation of restriction sites. M15 strains
were transfected with the corresponding plasmid for 30 s
at 42 °C, followed by five minutes in ice and 30-min recov-
ery at 37 °C in LB medium. Plates of LB contained
100 μg/mL of ampicillin and 30 μg/mL of kanamycin.
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for introducing the enzymatic restriction sites BamH1 and
Sal1 for directional insertion into pET28a+. The PCR-
amplified product was cloned into pCR®2.1-TOPO®,
digested with EcoRI and subcloned using standard
methods. The PCR amplifications were carried out using
the following oligonucleotides: Ba1Bam corresponds to 5’-
GGATCCATCGAGGGAAGGATTCTCGAATGTGTTT
TCTCATGC-3’, and Ba1S to 5’-GTCGACTTACTAA
ATCTTCAGACACAACTTGATC-3’. The PCR condi-
tions were: three minutes at 94 °C, 30 cycles for 30 s at
94 °C, one minute at 60 °C, one minute at 72 °C, and a
final extension of seven minutes at 72 °C. The PCR prod-
ucts and the corresponding plasmids were digested with
the corresponding restriction enzymes at 37 °C overnight.
PCR products were purified using the High Pure Plasmid
Isolation kit (Roche) before ligation. The ligation reaction
(20 μL) was carried out via T4 DNA ligase with a 10-fold
insert excess over plasmid for 16 h at 16 °C; ten microli-
ters of the ligation reaction was used to transfect compe-
tent E. coli XL1 Blue cells. Positive clones with the
expected insert were grown in LB ampicillin medium. The
plasmids of positive colonies were purified by means of
the same plasmid isolation kit (Roche). Plasmid constructsFig. 1 Gene construction of the plasmids carrying either pQE40HisrDHFRBa
sequences in pQE40HisrDHFRBa1 and pET28HisrBa1. b Schematic representwere verified by sequencing from both sites, the insert
boundaries to confirm the reading frame and conservation
of restriction sites. BL21 (DE3) strains were transfected
with the corresponding plasmid for 30 s at 42 °C, followed
by five minutes in ice and 30-min recovery at 37 °C in LB
medium. Plates of LB contained 30 μg/mL of kanamycin.
Thus, the plasmids essentially contained a pro-peptide,
a 6His-tag, a sequence coding for the amino acids recog-
nized by the protease (factor Xa) and the gene of Ba1.
The constructions were named pQE40HisrDHFRBa1
and pET28HisrBa1, and its products were abbreviated
HisrDFHRBa1 and HisrBa1, respectively (Fig. 1).
Production and purification of HisrDFHRBa1 and HisrBa1
The E. coli strains M15 and BL21 (DE3), cells expressing
the respective plasmids pQE40HisrDHFRBa1 and pET28
HisrBa1, were grown in LB medium. After the absorbance
at 600 nm reached 0.6 absorption units, the cultures were
induced with 0.1 mM IPTG (isopropyl-β-D-thiogalacto-
pyranoside) for 14 h at 21 °C. Cells were harvested by
centrifugation (9820 × g for 20 min) using a Beckman cen-
trifuge, model JA-14, recovered in washing buffer (50 mM
Tris–HCl, pH 8.0) and lysed with a BugBuster® protein1 or pET28HisrBa1. a The organization of the gene and amino acid
ation of the expression vectors
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centrifuged again (17,400 × g for 20 min) and the super-
natant was recovered. Moreover, the insoluble fraction
was resuspended twice with the washing buffer and
centrifuged under the same conditions. The recombin-
ant toxin was extracted from the soluble part and from
the inclusion bodies using 6 M guanidinium chloride
(GndHCl) in a 50 mM Tris-base, buffer, pH 8.0 and
centrifuged for 20 min in a Beckman centrifuge, model
JA-20 (17,400 × g for 20 min). The supernatant was
purified by affinity column. Purification of the recom-
binant Ba1 by Ni-NTA (Ni-nitrilotriacetic acid) affinity
column chromatography was performed according to
the instructions of the manufacturer (Qiagen, USA)
using denaturing conditions with buffer A (6 M
GndHCl in a 50 mM Tris-base buffer, pH 8.0) and
buffer B (6 M GndHCl in 50 mM Tris-base buffer,
containing 400 mM imidazole, pH 8.0). Buffer B was
eliminated by a second purification step under a high-
performance liquid chromatography system (Agilent,
series 1100), equipped with a binary pump and diode
array detector systems. An analytic C18 reverse-phase
column (Vydac 218 TP54) was run from solvent A
(0.1 % trifluoroacetic acid – TFA in water) to solvent B
(0.1 % TFA in acetonitrile) at 1 mL/min flow rate. The
absorbance was registered at 280 and 230 nm, and the
fractions were manually collected and freeze-dried. The
HPLC system previously described [10] was used for
this separation, and the gradient varied according to
type of protein to purified. For instance, for HisrD
FHRBa1 it was run from 0-60 % solvent B, during
60 min, and for HisrBa1 it was run from 20 % to 70 %
solvent B, for 50 min.
In vitro folding conditions and enzymatic cleavage
When needed, the recombinant proteins, HisrDFHRBa1
and HisrBa1, were vacuum dried and the cystines re-
duced using 50 mM DTT in 50 mM Tris-base buffer,
pH 8.0. The folding conditions were 2 M GndHCl in
200 mM Tris-base buffer, pH 8.0, containing 1 mM re-
duced glutathione (GSH)/0.1 mM oxidized glutathione
(GSSG). The folding reaction was carried out at room
temperature for 18 h, after which the products were sep-
arated by rpHPLC. The folded recombinant products,
HisrDFHRBa1 and HisrBa1, were cleaved by FXa using a
ratio 50:1 in 20 mM Tris-base buffer, pH 8.0, at 37 °C
for five hours, and the recombinant Ba1 (rBa1) eluted
from a reverse-phase column, vacuum dried and stored
at−20 °C. The identity of the rBa1 was confirmed by
both automatic Edman degradation and mass spectrom-
etry analysis using a Finnigan LCQDUO ion trap mass
spectrometer (San Jose, USA). These techniques are
currently employed in our laboratory and have been
reported elsewhere [11].Ba1 chemical synthesis
Ba1 was chemically synthesized by a solid-phase method
using the Fmoc methodology on an Applied Biosystems
433A peptide synthesizer. Fmoc-Ile-Wang resin (Chem-
Pep Inc.) was used to provide the first residue with a free
carboxyl at the C-terminal of synthetic sBa1 (sBa1).
Chemical synthesis, cleavage and deprotection of peptide
resins were performed as previously described [2]. The
crude synthetic peptide was dissolved in 20 % aqueous
acetonitrile, and the reduced insecticidal toxin separated
by rpHPLC on a semi-preparative C18 column (Vydac
218 TP54) using a gradient from solvent A (0.1 % TFA
in water) to solvent B (0.1 % TFA in acetonitrile) at
2 mL/min flow rate. The six free cysteine residues were
allowed to oxidize by air exposure for 18 h at 5 °C in
a 2 M aqueous ammonium acetate solution containing
1 mM reduced glutathione/0.1 mM oxidized glutathi-
one. The biologically active synthetic toxin was puri-
fied on an analytical C18 rpHPLC column using a gradient
from solvent A (0.1 % TFA in water) to solvent B (0.1 %
TFA in acetonitrile) at 1 mL/min flow rate. The structural
identity between synthetic and natural peptides was veri-
fied by co-elution experiments and by mass spectrometry.
Biological activity
The protocol employed for assaying the in vivo activity
of HisrDFHRBa1, HisrBa1, rBa1 (pQE40), Ba1 (pET28)
and sBa1 utilized house crickets (Acheta domesticus).
Crickets were injected intrathoracically between the sec-
ond and third pair of legs, with 5 μL of five different
doses of each toxin previously dissolved in distillated
water. Groups of five individuals were injected with at
least an equivalent to produce the 100 % mortality of the
house crickets based on the native Ba1.
Committee approval
The present study was approved by the Committee of
Animal Welfare of the Institute of Biotechnology,
UNAM. The number of animals was kept to a minimum
required to validate the experiments.Results and discussion
Gene cloning and recombinant expression
As described in the Methods section, a gene coding for
the Ba1 toxin was obtained from a cDNA library. The
PCR products with the expected size (~164 bp) were
purified using the High Pure Plasmid Isolation Kit
(Roche), cloned into pCR®2.1-TOPO® (Invitrogen) and
its nucleotide sequence was verified. The Ba1 gene was
cloned in two plasmids harboring long pro-peptide
structures to facilitate the expression of the recombinant
proteins. In the expression vector pQE40 that coded
for 247 residues (four for initial protein translation –
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reductase – DHFR, two for the restriction site, four for
the Factor Xa proteolytic cleavage region and 39 for the
mature Ba1 peptide, pQE40HisrDHFRBa1), and in the
expression vector pET28a+ that coded for 77 residues
(four for initial protein translation – MRGS, six for the
His-tag, 24 extra residues, four for the Factor Xa proteo-
lytic cleavage region before the 39 residues of the mature
Ba1 peptide – pET28HisrBa1). In brief, the gene product
of the plasmid pQE40 encloses a 26 kDa DHFR pro-
peptide (HisrDHFRBa1), while the gene product of the
plasmid pET28 encloses a 8 kDa pro-peptide (HisrBa1)
(Fig. 1).
Expression, purification, in vitro folding and enzymatic
cleavage
The E. coli strains M15 and BL21 were transformed,
respectively, with plasmids pQE40HisrDHFRBa1 and
pET28HisrBa1. Cells of either M15 or BL21 obtained
after induction with IPTG were decanted by centrifuga-
tion, resuspended and ruptured with the BugBuster®
protein extraction reagent as described in the Methods
section. After solubilization with GndHCl the supernatantFig. 2 SDS-PAGE showing the expression of pQE40HisrDHFRBa1 or pET28H
molecular weight markers (MWM). Lane 1, cells with vector pQE40; lane 2,
supernatant; lane 5, inclusion bodies; lanes 6 and 7, DHFR-Ba after affinity c
the molecular weight markers (MWM). Lane 1, cells without IPTG induction
bodies; lanes 5, first affinity chromatography elution; lanes 6 and 7, first and
chromatography. The protein content applied in each lane was between 5was purified by affinity column. Figure 2 shows the SDS-
PAGE of the expressed proteins obtained in the presence
or absence of IPTG, and before and after purification by
affinity column. For protein expression in M15 cells, lane
3 clearly shows the presence of an intense protein band
(indicated by an arrow) with the expected molecular
weight for the protein HisrDHFRBa1, which is more in-
tense in lane 5 (cell inclusion bodies); lanes 6 and 7 show
the result of the purification of HisrDHFRBa1 using agar-
ose nickel affinity columns, where a minor increase in
purity was observed (Fig. 2a). For protein expression in
BL21 cells, lanes 2 to 7 shows almost imperceptible
amounts of HisrBa1 (indicated by an arrow), but lanes 8
and 9 show an intense band of the histidine-tagged
HisrBa1 (8 kDa) purified using nickel affinity agarose
columns (Fig. 2b). Although an intense band of a 25 kDa
protein was observed in lanes 8 and 9, this protein was
not observed during purification by rpHPLC. Therefore, it
was assumed that HisrBa1 might form a tetramer under
SDS-PAGE conditions.
Imidazole eluates from the affinity chromatography col-
umns were directly loaded into a C18 column by rpHPLC
separation (Fig. 3). The rpHPLC profile of the separationisrBa1. a Gel of pQE40HisrDHFRBa1 expression. Left lane shows the
cells without IPTG induction; lane 3, cells with IPTG induction; lane 4,
hromatography. b Gel of pET28HisrBa1 expression. Left lane shows
; lane 2, cells with IPTG induction; lane 3, supernatant; lane 4, inclusion
second wash with 20 mM Imidazol; l 8 and 9, HisrBa1 after affinity
and 10 μg
Fig. 3 rpHPLC separation of oxidized pQE40HisrDHFRBa1 or pET28HisrBa1 from affinity chromatography. a The fractions from NiNta were
separated employing rpHPLC (C18 column) using a gradient from 0 to 60 % B in 60 min at 1 mL/min. b The fractions from NiNta were separated
using rpHPLC (C18 column) using a gradient from 0 to 50 % B in 50 min at 1 mL/min
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molecular mass of 28,289.0 Da (Fig. 3a). Although the
expected theoretical molecular mass was 28,274.0 Da, the
chromatographic peak for this fraction showed 15 amu
higher than the expected, which could be the consequence
of the oxidation of one of its seven methionines to
methionine sulfoxide (Δ15.9 amu). On the other hand, the
rpHPLC profile of HisrBa1 separation shows a single
sharp peak (Fig. 3b) with an unexpected experimental mo-
lecular mass of 8274.8 Da that represents a difference of
131 Da below the expected theoretical mass of 8405.8 Da.
The difference of 131 Da represents the molecular weight
of a methionine, which has been reported to undergo a
post-translational processing in E. coli when the second
residue of a nascent peptide is a short one [12]. In this
case, the second residue of HisrBa1 is glycine (see Fig. 1).
Therefore, the experimental mass found of 8274.8 Da
corroborates this post-translational processing. The yields
of the recombinant insecticidal toxins HisrDHFRBa1 and
HisrBa1, after rpHPLC purification, starting with 1 L of
cell culture, were 100 μg/L and 900 μg/L, respectively.The purified protein fractions HisrDHFRBa1 and HisrBa1
were vacuum dried, resuspended and injected into house
crickets, but they were not lethal to the insects (Table 1).
These results suggested missing folded proteins and prom-
pted us to conduct in vitro reduction-oxidation steps for
each protein; therefore, they were reduced and folded under
in vitro conditions in the presence of reduced and oxidized
glutathione as a redox pair to improve the correct folding
of the cystines [13].
The rpHPLC profile of the separation of HisrDHFRBa1
after folding conditions also showed a single broad frac-
tion without insecticidal activity. However, the rpHPLC
profile of the separation of HisrBa1 displayed three main
chromatographic peaks (Fig. 4), labeled from 1 to 3, with
the expected molecular mass of 8274.8 Da. Thus, three
main isoforms from HisrBa1 were generated during oxi-
dation of the thiol groups for formation of the disulfide
bridges; here only the chromatographic peak number 1
produced paralytic activity when injected in house crickets
(Table 1). In Fig. 4, we have superimposed both the results
of the rpHPLC separation of the multiple oxidized forms
Table 1 Insecticidal effects of nBa1, DHFRBa1, HisrBa1, rBa1 and sBa1 on house crickets
Peptide MW (Da) Dose (μg/g cricket) Effective Ba1 dose (μg/g cricket) Observation
nBa1 4,406.7 12.1a 12.1 Dead
DHFRBa1 28,289.0 200.0 31.2 No effect
HisrBa1 8,274.3 90.7 48.3 No effect
HisrBa1 (peak 1) 8,274.3 79.3 42.3 Paralysis/survived
rBa1 (pEQ40) 4,406.4 12.9 12.9 Dead
rBa1 (pET28) 4,406.4 12.9 12.9 Dead
sBa1 4,406.8 12.2 12.2 Dead
aEach group was represented by five house crickets
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chromatogram.
Since HisrDHFRBa1, after folding conditions, was
eluted in a broad single peak as a high-molecular-weight
protein, it was difficult to determine whether it con-
tained multiple oxidized forms as HisrBa1. To prove the
existence of multiple forms in HisrDHFRBa1 another
type of protein separation may be used. Because the
in vitro folded HisrDHFRBa1 and HisrBa1 were not fully
active on insects, the enzymatic cleavage with FXa was
conducted to release the mature peptide Ba1 from their
N-terminal pro-peptide.
Figure 5 shows the enzymatic cleavage of HisrDHFRBa1
and HisrBa1. Figure 5a shows a multiple unspecific cleav-
age of HisrDHFRBa1 at different incubation times, and
rBa1, from HisrDHFRBa1, which was obtained in small
quantities. On the other hand, the digestion of HisrBa1
was straightforward but rBa1 was also found in minute
amounts (Fig. 5b).
Chemical synthesis of Ba1
Ba1 was synthesized in its free carboxyl-terminus form.
The overall assembly and cleavage yield of Ba1 was 55 %
according to theoretical values of the peptidyl resin and
the calculated mass increase for 0.1 mmol peptide toFig. 4 rpHPLC separation of the in vitro folding of HisrBa1. The component
rpHPLC (C18 column) using a gradient from 0 to 50 % B in 50 min at 1 mL
same elution conditions shows the retention time of the reduced HisrBa1produce 242 mg of crude synthetic peptide. The yield
after chromatographic purification of the linear peptide
was 31.4 mg (7.1 %) and after refolding was 11 mg
(2.5 %). Because of the hydrophobic exposure in an un-
structured peptide, the retention time of the unfolded
sBa1 was larger than that of the folded sBa1 (Fig. 6). The
structural identity between the synthetic peptide sBa1
and the native one was verified by mass spectrometry
and in co-injection experiments, native Ba1 (nBa1) and
synthetic Ba1 (sBa1) co-eluted in a single peak, indicat-
ing that they have similar retention times and suggesting
a similar secondary and 3D structure (data not shown).
Biological activity
The well-folded recombinant and chemically synthesized
insecticidal peptides were active against house crickets
(Acheta domesticus). Table 1 shows the biological activity
of the recombinant and chemically synthetic Ba1, which
were tested in groups of five crickets. Although the LD50
of nBa1 was calculated in 10.8 μg/g of cricket, a dose of
12.1 μg/g of cricket was enough to kill all of them. As
mentioned, the uncleaved recombinant HisrDHFRBa1
and HisrBa1 were not biological active, a result that may
be attributable to the large amount of extra N-terminal
residues for Ba1 in HisrDHFRBa1 (84 %) and in HisrBa1s of the in vitro folding reaction of HisrBa1 were separated employing
/min. A superimposed chromatographic rpHPLC profile under the
Fig. 5 rpHPLC separation of rBa1 from HisrDHFRBa1 and HisrBa1 using FXa. (a) Enzymatic hydrolysis of HisrDHFRBa1 using FXa where rBa1
(asterisk) was separated by rpHPLC (C18 column) with a gradient from 10 to 60 % B in 50 min at 1 mL/min. (b) Enzymatic hydrolysis of HisrBa1
using FXa, rBa1 was separated by rpHPLC (C18 column) with a gradient from 0 to 60 % B in 60 min at 1 mL/min. A superimposed
chromatographic rpHPLC profile under the same elution conditions shows the retention time of the nBa1. The fact that rBa1 and nBa1 eluted at
the same retention time suggests similar secondary and tertiary structures
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and molecular recognition towards the insect cellular
target of Ba1.
Conclusions
Synthesis of cysteine rich peptides by chemical means
has recently attracted more interest, as they allow the
production of wholly biologically active molecules by
either combinations of solid-phase peptide synthesis or
native chemical ligation [14]. However, because of the
great amount of β-sheets, and paucity of random and
α-helix structures in this molecule type, only peptides
containing less than 50 amino acids can be reliably pre-
pared with acceptable yields and purity. Hence, a strategyof peptide segment condensation could be used in which
peptide fragments are subjected to chemical ligation
methods. A drawback for chemical synthesis could be pro-
teins that require post-translational and conformational
modifications in order to render biological activity. There-
fore, oxidative folding has to be performed usually in a
one-step oxidative folding procedure in the presence of a
redox pair that is sufficient for spontaneous peptide fold-
ing. Consequently, chemical synthesis could be a less
expensive and time-consuming procedure as compared to
the heterologous expression in spite of the high cost of
chemical reagents.
On the other hand, heterologous expression of cysteine-
rich peptides is currently a widely used technique and
Fig. 6 Chromatographic purification of the chemically synthesized Ba1. rpHPLC profile of Ba1 before and after folding experiments. Separation
was performed using a gradient from 0 to 60 % B in 60 min at 1 mL/min. The dashed line represents the reduced form of Ba1, which eluted later
and it is much more hydrophobic than the folded sBa1
Clement et al. Journal of Venomous Animals and Toxins including Tropical Diseases  (2015) 21:19 Page 9 of 10diverse expression systems have been reported. Protein ex-
pression in E. coli is relatively simple and less expensive
compared to yeast or eukaryotic systems; however, a major
drawback is that the recombinant protein often needs to
be fused to a carrier protein to increase its solubility and
thus avoid formation of inclusion bodies [15]. This fusion
protein needs to be released during or after purification of
the protein of interest via enzymatic or chemical cleavage
to render functional proteins, which results in a decreased
yield as we have observed (see Table 1). In addition, fusion
proteins are not necessarily properly folded and production
of cysteine-rich peptides could be inactive as we have
shown during the expression of HisrDHFRBa1.
In this work, both heterologous expression systems
pQE40HisrDHFRBa and pET28HisrBa1 produced fully
active toxins but with low yields in relation to time and
material efforts. The active fraction rBa1 represented
only the 15.6 % of effective peptide in the recombinant
HisrDHFRBa1 protein, and it represents 53.3 % in the
recombinant HisrBa1 peptide. In this report, the less
exigent synthetic process, in time and materials, was the
chemical synthesis of Ba1. Although the chemical
synthesis of cysteine-rich peptides required an in vitro
folding step, it was the same for the recombinant
HisrBa1, and perhaps for the HisrDHFRBa1, which may
be produced in multiple oxidized forms; so for all of
them a folding step may be needed. An alternative to the
recombinant efficacy of heterologous expression systems
of short cysteine-rich peptides might be recombinant
expression in a soluble form with shorter N-terminal
pro-peptides, which could avoid folding steps and
increase the yield for effective and biological active
cysteine-rich neurotoxin peptides. In this work, we com-
pare the biological and chemical synthesis of an insecti-
cidal peptide from spider venom; this comparison may
be useful when synthesizing similar cysteine-rich pep-
tides from arthropods.Abbreviations
TFA: Trifluoroacetic acid; rpHPLC: Reverse-phase HPLC; Ba1: Toxin 1 from the
spider Brachypelma albiceps.
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